These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 25921514)

  • 1. Mitochondrial and apoptotic in vitro modelling of differential HIV-1 progression and antiretroviral toxicity.
    Morén C; Bañó M; González-Casacuberta I; Catalán-Garcia M; Guitart-Mampel M; Tobías E; Cardellach F; Pedrol E; Peraire J; Vidal F; Domingo P; Miró Ò; Gatell JM; Martínez E; Garrabou G
    J Antimicrob Chemother; 2015 Aug; 70(8):2330-6. PubMed ID: 25921514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 promonocytic and lymphoid cell lines: an in vitro model of in vivo mitochondrial and apoptotic lesion.
    Morén C; González-Casacuberta I; Álvarez-Fernández C; Bañó M; Catalán-Garcia M; Guitart-Mampel M; Juárez-Flores DL; Tobías E; Milisenda J; Cardellach F; Gatell JM; Sánchez-Palomino S; Garrabou G
    J Cell Mol Med; 2017 Feb; 21(2):402-409. PubMed ID: 27758070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.
    Sternfeld T; Schmid M; Tischleder A; Mudra S; Schlamp A; Kost BP; Gruber R; Youle M; Bogner JR; Goebel FD
    Antivir Ther; 2007; 12(5):769-78. PubMed ID: 17713160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1-infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressors.
    Peraire J; Miró O; Saumoy M; Domingo P; Pedrol E; Villarroya F; Martínez E; López-Dupla M; Garrabou G; Sambeat MA; Deig E; Villarroya J; Chacón MR; López S; Fontanet A; Holmstrom M; Giralt M; Gatell JM; Vidal F
    Curr HIV Res; 2007 Sep; 5(5):467-73. PubMed ID: 17896966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.
    Miró O; Villarroya J; Garrabou G; López S; Rodríguez de la Concepción M; Pedrol E; Martínez E; Giralt M; Gatell JM; Cardellach F; Casademont J; Villarroya F
    Antivir Ther; 2005; 10(8):945-51. PubMed ID: 16430200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.
    Hall AM; Edwards SG; Lapsley M; Connolly JO; Chetty K; O'Farrell S; Unwin RJ; Williams IG
    Am J Kidney Dis; 2009 Dec; 54(6):1034-42. PubMed ID: 19783343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial membrane potential and apoptosis of blood mononuclear cells in untreated HIV-1 infected patients.
    Sternfeld T; Tischleder A; Schuster M; Bogner JR
    HIV Med; 2009 Sep; 10(8):512-9. PubMed ID: 19496834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of circulating cytochrome c with clinical manifestations of antiretroviral-induced toxicity.
    Langs-Barlow A; Selvaraj S; Ogbuagu O; Shabanova V; Shapiro ED; Paintsil E
    Mitochondrion; 2015 Jan; 20():71-4. PubMed ID: 25435346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral T-cell apoptosis is not differentially affected by antiretroviral regimens in HIV-infected patients.
    Feuth T; van Baarle D; Hoepelman AI; Arends JE
    Antivir Ther; 2013; 18(8):1021-5. PubMed ID: 23732862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapy.
    Fabre-Mersseman V; Tubiana R; Papagno L; Bayard C; Briceno O; Fastenackels S; Dudoit Y; Rostane H; Salmon D; Costagliola D; Caby F; Sauce D; Viard JP; Appay V
    AIDS; 2014 Nov; 28(18):2677-82. PubMed ID: 25493593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
    Maggiolo F; Roat E; Pinti M; Nasi M; Gibellini L; De Biasi S; Airoldi M; Ravasio V; Mussini C; Suter F; Cossarizza A
    Antivir Ther; 2010; 15(1):51-9. PubMed ID: 20167991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Label-free proteomic analysis of PBMCs reveals gender differences in response to long-term antiretroviral therapy of HIV.
    Zhang L; Wang Z; Chen Y; Zhang C; Xie S; Cui Y; Wang Z
    J Proteomics; 2015 Aug; 126():46-53. PubMed ID: 26045010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn.
    Hernàndez S; Morén C; López M; Coll O; Cardellach F; Gratacós E; Miró O; Garrabou G
    AIDS; 2012 Feb; 26(4):419-28. PubMed ID: 22156962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.
    Calza L; Vanino E; Salvadori C; Manfredi R; Colangeli V; Cascavilla A; Di Bari MA; Motta R; Viale P
    HIV Clin Trials; 2014; 15(1):1-13. PubMed ID: 24518210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis resistance in HIV-1 persistently-infected cells is independent of active viral replication and involves modulation of the apoptotic mitochondrial pathway.
    Fernández Larrosa PN; Croci DO; Riva DA; Bibini M; Luzzi R; Saracco M; Mersich SE; Rabinovich GA; Martínez Peralta L
    Retrovirology; 2008 Feb; 5():19. PubMed ID: 18261236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort.
    Rokx C; Fibriani A; van de Vijver DA; Verbon A; Schutten M; Gras L; Rijnders BJ;
    Clin Infect Dis; 2015 Jan; 60(1):143-53. PubMed ID: 25273080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of mitochondrial DNA mutations in HIV-infected treatment-experienced individuals.
    Li M; Foli Y; Liu Z; Wang G; Hu Y; Lu Q; Selvaraj S; Lam W; Paintsil E
    HIV Med; 2017 Jan; 18(1):45-55. PubMed ID: 27328746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adipogenic/lipid, inflammatory, and mitochondrial parameters in subcutaneous adipose tissue of untreated HIV-1-infected long-term nonprogressors: significant alterations despite low viral burden.
    Vidal F; Domingo P; Villarroya F; Giralt M; López-Dupla M; Gutiérrez M; Gallego-Escuredo JM; Peraire J; Viladés C; Veloso S; Mateo G; Guallar JP; Richart C
    J Acquir Immune Defic Syndr; 2012 Oct; 61(2):131-7. PubMed ID: 22580565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients.
    Mologni D; Citterio P; Menzaghi B; Zanone Poma B; Riva C; Broggini V; Sinicco A; Milazzo L; Adorni F; Rusconi S; Galli M; Riva A;
    AIDS; 2006 Feb; 20(4):567-74. PubMed ID: 16470121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.